Goodwin Procter LLP advised InterVenn Biosciences on the deal. InterVenn Biosciences announced its $34 million Series B fundraising. The latest round was led by Anzu Partners…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
